Advanced Cell Therapeutics

















60 Minutes Report (click here for link)

The following 200 case studies have been accumulated over 3 years and provide insight into the benefits and experiences of some individuals in their own words.

300 additional case studies are currently being analysed for posting in the near future. To date over 350 MS treatments have been facilitated by ACT, unposted data is available by request.

Significant clinical benefits have been categorized on a scale from 1 to 3.
1) Mild improvements
2) Strong lasting improvements
3) No further signs of disease

It is important to note that in 2003 the incidence of significant clinical benefit using only Purified cells was estimated at 40-50%. In 2004/2005 treatments using Purified and Potentiated cells have generated an estimated 80% incidence of significant clinical benefit. In all treatments no side effects were reported.

Case Studies are grouped by condition and arranged in descending order with the most recent treatments first. Particularly significant or detailed case studies are denoted (marked *) for priority reading.

NEUROLOGICAL DISEASE
Multiple Sclerosis (MS)
Amyotrophic Lateral Sclerosis (ALS)
Parkinson's Disease (PD)
Cerebral Palsy (CP)
Autism
Guilliame Barre
Transverse Myelitis
Basal Ganglia
Supranuclear Palsy
Hungtington's Disease
Rhett's Syndrome
Migraine Headaches
Stroke

NEUROLOGICAL INJURY
Spinal Cord Injury
Traumatic Brain Injury

BLOOD CANCER
Acute Lympholastic Leukaemia
Multiple Myeloma
Non-Hodgkins Lymphoma

BLOOD DISEASE
Blood Platelet Disorder
Refractory Anemia
Myelodysplasia

ORGAN/TISSUE CANCERS (IMMUNOTHERAPY)
Breast Cancer
Prostate Cancer
Colon Cancer
Pancreatic Cancer
Lung Cancer
Liver Cancer
Malignant Melanoma
Kidney Cancer
Chemo Rescue

VIRAL CONDITIONS
HIV 1 (no AIDS diagnosis)
AIDS (advanced)
Lyme Disease

LIVER DISEASE
Hepatitis B
Hepatitis C
Cirrhosis
Fibrosis

OCULAR CONDITIONS
Retinitis Pigmentosa
Macular Degeneration
Glaucoma
Cortical Blindness

AUTO IMMUNE CONDTIONS
Crohn's Disease
Rheumatoid Arthritis
Lupus

DIABETES
Type 2 (Adult Onset)
Type 1 (Child Onset)

HEART DISEASE
Myocardial Infarction
Dilated Cardiomyopathy
Atherosclerosis
Congestive Heart Failure

RENAL DISEASE
Macroscopic Hematuria

SKIN DISEASE
Polymyositis

LUNG DISEASE
Progressive Dyspnea
COPD

HEARING
Deafness
Injury related hearing loss
Infection related hearing loss

HELLO WORLD




The primary purpose of the following case studies is to assess the benefits of cord blood stem cell therapy in individuals in compromised states of health. Cord Blood Stem Cell Therapy does not serve as a substitute for a participant's current medical care and treatment, nor do the cord blood stem cell therapies provided in the case studies intend to serve as prevention, treatment or cure for any disease, ailment, or condition. A secondary purpose of the studies is to gather data for possible scientific publication or presentation as well as to determine if longer-term studies are warranted.

Participants are asked to provide periodic progress reports and medical documentation. The initial study period is approximately one year. The reasonable expected benefit of the study is to gain knowledge about the effects of cord blood stem cell therapy for individuals in compromised states of health. There may or may not be direct health benefits to participants undergoing the therapy, and positive results are not guarenteed. Participants are not compensated for participating in the study. All medical treatment and costs associated with treatment is the responsibility of the participants.